Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9NPF2
UPID:
CHSTB_HUMAN
Alternative names:
Chondroitin 4-O-sulfotransferase 1; Chondroitin 4-sulfotransferase 1
Alternative UPACC:
Q9NPF2; A8K4F8; Q9NXY6; Q9NY36
Background:
Carbohydrate sulfotransferase 11, also known as Chondroitin 4-O-sulfotransferase 1, plays a pivotal role in the biosynthesis of chondroitin sulfate. This enzyme is crucial for the proper formation of cartilage and the maintenance of extracellular matrices, highlighting its significance in skeletal development and cellular functions.
Therapeutic significance:
The enzyme's association with Osteochondrodysplasia, characterized by skeletal defects and limb malformations, underscores its therapeutic potential. Targeting Carbohydrate sulfotransferase 11 could lead to innovative treatments for skeletal dysplasia and related disorders, offering hope for affected individuals.